Novavax

Novavax

World Rank (Jan-05-2024)
11,359
Market Cap (Jan-05-2024)
0.613 Billion USD
World Rank (Jul-30-2023)
10,617
Market Cap (Jul-30-2023)
0.708 Billion USD
World Rank (Jan-07-2022)
1,955
Market Cap (Jan-07-2022)
9.580 Billion USD
World Rank (Jan-01-2021)
2,119
Market Cap (Jan-01-2021)
7.527 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
NVAX
Market Cap (Mar-08-2026)
1.63
Employee Count
375
Employee Count as of Date
As on 2020
Headquarters City/State
Maryland
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
1,598 Million USD
Annual Operating Income in USD
-664 Million USD
Annual Net Income in USD
-657 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
2,258 Million USD
Total Liabilities in USD
2,892 Million USD
Total Equity in USD
-634 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector
Healthcare
Biotechnology
Technology
HealthCare Products
Company Website
NOVAVAX
Wikipedia
Wikipedia
Yahoo
Yahoo @ Frankfurt
Company Profile

Novavax is a Late Stage Biotechnology company that promotes improved global health through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company annual revenue is 157.0 million USD and 375 employees as on 2020. The headquarters is in USA.

Annual Results Summary

NOVAVAX - Yearly Revenue and Net Income - in Million USD:

Year - EndingRevenueOperating IncomeNet Income
Dec-20211,146-1.686 (Loss)-1,743 (Loss)
Dec-2020475-416 (Loss)-418 (Loss)
Dec-201918-129 (Loss)-132 (Loss)
Dec-201834-173 (Loss)-184 (Loss)
Balance Sheet Summary

Total Assets as on Dec-2021 was 2,576 Million USD.

Total Liabilities as on Dec-2021 was 2,928 Million USD.

Total Equity as on Dec-2021 was -351 Million USD.

Founded Year
1987
Stock Exchange
Nasdaq
Frankfurt
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Share